Quantcast

CSA Medical Appoints William H. Floyd President and CEO

December 2, 2010

BALTIMORE, Dec. 2, 2010 /PRNewswire/ — CSA Medical, Inc. (www.CSAmedical.com) today announced the appointment of William H. Floyd as incoming president, CEO and member of the board of directors. Floyd brings to the company more than 20 years of medical device experience, including market development roles commercializing disposables, implants, capital equipment and monitoring systems.

“We are thrilled to have Bill join the company and lead our efforts to create a world class medical device company,” said Vince Owens, Chairman of the CSA Medical board of directors. “The company has made steady progress growing our customer and procedure base, and we believe that Bill has the background and experience needed to take our business to the next level of commercialization, including leading product development, clinical trials, regulatory, sales and marketing.”

Prior to joining CSA Medical, Bill served as vice president of U.S. sales for Covidien following the sale of Aspect Medical Systems to Covidien in 2009. Previously, he was executive vice president of worldwide sales and marketing at Aspect Medical Systems, Inc. Throughout a seven-year period, he managed Aspect from $19 million in revenue and a $20 million operating loss to more than $110 million in revenue and $16 million operating profit. Earlier in his career, Bill spent five years serving as vice president of marketing at Boston Scientific. In this position, he developed and executed the urology division’s five year strategic plan focused on growth and diversification. His efforts led to two acquisitions and numerous licensing and distribution agreements. Previously, Bill held numerous senior sales and marketing positions with Johnson & Johnson (Codman & Shurtleff) and Procter and Gamble. Bill earned a bachelor’s degree from the University of Vermont.

“CSA Medical’s spray cryotherapy is a tremendously exciting new technology that holds promise to stop disease processes and dramatically improve the quality of life for millions of patients,” said Floyd. “I look forward to working with our team to bring the benefits of this technology to more patients across the globe as we expand our customer and procedure base.”

CSA Medical, Inc develops and manufactures a proprietary therapeutic interventional treatment platform, the CryoSpray Ablation(TM) System, that delivers therapeutic doses of a cryogen to flash freeze and destroy diseased tissue inside the body. The Company is the first to harness the power of extreme cold (-196 C) liquid nitrogen therapeutic energy delivery inside the body. To learn more, please visit www.CSAmedical.com.

SOURCE CSA Medical, Inc.


Source: newswire



comments powered by Disqus